Table 2.
Clinicopathologic features and level of TFPI-2 protein in the TFPI-2 positive group
| Category | No. of cases | Meandensity of TFPI-2 Mean± SD | Statistics value | p value | |
|---|---|---|---|---|---|
| Age |
≤55 |
74 |
0.324±0.061 |
t=0.302 |
0.764 |
| |
>55 |
47 |
0.327±0.052 |
|
|
| Tumor size |
≤2 cm |
56 |
0.351±0.061 |
t=4.948 |
0.001 |
| |
>2 cm |
65 |
0.303±0.044 |
|
|
| Skin involvementa |
No |
96 |
0.336±0.057 |
t=4.252 |
0.001 |
| |
Yes |
25 |
0.284±0.038 |
|
|
| LN metastasis |
0 |
70 |
0.348±0.055 |
F=12.896b |
0.001 |
| |
1-3 |
22 |
0.292±0.043 |
|
|
| |
4-9 |
15 |
0.316±0.048 |
|
|
| |
10- |
13 |
0.272±0.038 |
|
|
| |
Unknown |
1 |
|
|
|
| Histologic grade |
≤II |
71 |
0.339±0.057 |
t=3.389 |
0.001 |
| |
>II |
50 |
0.305±0.052 |
|
|
| Vessel invasion |
Absence |
109 |
0.333±0.054 |
t=5.172 |
0.001 |
| |
Presence |
12 |
0.251±0.030 |
|
|
| Clinical stagec |
I |
35 |
0.375±0.053 |
Chi-Square=43.867c |
0.001 |
| |
II |
52 |
0.317±0.048 |
|
|
| |
III |
34 |
0.286±0.034 |
|
|
| ER |
(-) |
43 |
0.327±0.055 |
t=0.253 |
0.801 |
| |
(+) |
77 |
0.324±0.059 |
|
|
| |
Unknown |
1 |
|
|
|
| PR |
(-) |
63 |
0.319±0.055 |
t=-1.211 |
0.228 |
| |
(+) |
57 |
0.332±0.060 |
|
|
| |
Unknown |
1 |
|
|
|
| HER-2 |
(-) |
62 |
0.333±0.059 |
t=1.361 |
0.176 |
| |
(+) |
55 |
0.318±0.056 |
|
|
| |
Unknown |
4 |
|
|
|
| Tumor type |
IDCd |
98 |
0.324±0.057 |
t=0.488 |
0.626 |
| Non-IDCe | 23 | 0.330±0.059 |
a skin involvement include: edema, redness, nodularity, or ulceration of the skin.
b Post Hoc Multiple Comparisons(LSD) shows difference of TFPI-2 expression is only present in the group without LN metastasis and the other groups.
c Post Hoc Multiple Comparisons(Games-Howell) shows difference of TFPI-2 expression was significant among the groups (Nonparametric Test).
d IDC, invasive ductal carcinoma.
e Non-IDC include: invasive lobular carcinoma, mucinous or colloid carcinoma, medullary carcinoma, metaplastic carcinoma.